Objective To evaluate the safety and efficacy of gefitinib as second-line or even third-line
treatment for previously treated patients with locally advanced or metastatic non-small cell …

Introduction: Gefitinib is an EGFR tyrosine kinase inhibitor (EGFR-TKI) that demonstrated
efficacy in patients with advanced non-small cell lung cancer (NSCLC) across therapy lines …

The study by Fukuoka et al 1 published in Journal of Clinical Oncology in 2003 was a
randomized phase II study which investigated two doses of gefitinib (250 mg daily and 500 …

Purpose The use of gefitinib, the first drug approved to inhibit the epidermal growth factor
receptor tyrosine kinase, is indicated in patients with non–small-cell lung cancer with tumors …

Introduction: There is no published data in Nepal regarding the use of gefitinib in patients
with non-small cell lung cancer (NSCLC). Therefore, a retrospective analysis was conducted …

Gefitinib (Iressa™), the first commercially available epidermal growth factor receptor-tyrosine
kinase (EGFR-TK) inhibitor, is indicated in the management of patients with locally …

Background The objective of this study was to evaluate the efficacy and toxicity of gefitinib as
a first-line therapy in patients with advanced non-small cell lung cancer (NSCLC). Methods …

Opinion statement Gefitinib is a small molecule that specifically inhibits the tyrosine kinase
activity of the epidermal growth factor receptor (EGFR) type 1 by interfering with the …

Getinib (IressaTM, AstraZeneca) is a well-known inhibitor of the tyrosine kinase epidermal
growth factor receptor (EGFR), active in patients affected by non-small cell lung cancer …

Background: Lung cancer is the leading cause of cancer death in the world. In advanced
NSCLC, chemotherapy is the standard treatment strategy, but it has unfavorable side effects …